Novo Nordisk A/S (NYSE:NVO) Short Interest Update

Novo Nordisk A/S (NYSE:NVO) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totaling 19,927,815 shares, a drop of 19.3% from the March 15th total of 24,696,357 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily trading volume, of 18,061,163 shares, the days-to-cover ratio is presently 1.1 days.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded up $0.07 during mid-day trading on Thursday, reaching $40.88. 16,046,105 shares of the company were exchanged, compared to its average volume of 15,982,709. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The firm’s 50-day simple moving average is $40.22 and its two-hundred day simple moving average is $48.57. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a market cap of $182.53 billion, a PE ratio of 11.78, a price-to-earnings-growth ratio of 9.62 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were given a dividend of $1.2751 per share. This represents a yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 50.43%.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Opened a strategic partnership with OpenAI to deploy advanced AI across drug discovery, manufacturing and commercial operations — aimed at accelerating R&D, improving efficiency and helping Novo defend its lead in obesity/diabetes therapeutics. NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up
• Positive Sentiment: UK regulator approved a single‑dose 7.2 mg Wegovy pen for adults, expanding Wegovy’s dosing options and market availability in a major market. This is a near-term commercial win for Novo’s obesity franchise. UK approves Novo Nordisk single-dose 7.2mg Wegovy pen for adults
• Positive Sentiment: New study (pre-peer-review) suggests semaglutide may preserve lean body mass better than Eli Lilly’s tirzepatide — a data point investors could reward as it supports semaglutide’s clinical profile vs. a key competitor. Novo weight-loss drug may preserve lean body mass better than Lilly’s, study finds
• Positive Sentiment: Regulatory pressure on a competitor: Eli Lilly received an FDA request for more safety data on its oral weight‑loss pill, which could slow competitor momentum and indirectly benefit Novo’s market share. Lilly Stock Dips on FDA Request for More Foundayo Safety Data. Is the Market Reaction Overblown?
• Neutral Sentiment: Novo is advancing etavopivat into late‑stage trials for thalassemia, signaling diversification beyond obesity/diabetes but with longer time and development risk before meaningful commercial impact. Novo Nordisk’s Etavopivat Trials Put Rare Blood Disorders In Focus
• Neutral Sentiment: Company reportedly added ~2,000 staff this year — supports scaling commercial and R&D capacity for launches but may increase near‑term operating costs. Novo Nordisk has reportedly added 2,000 to workforce this year
• Neutral Sentiment: Analyst commentary (Zacks blog) highlights Novo among healthcare names — useful for sentiment but not a direct catalyst. The Zacks Analyst Blog Highlights Netflix, PepsiCo, Novo Nordisk, Hawthorn Bancshares and Park Aerospace
• Negative Sentiment: Rising generic competition: India’s Hetero targets annual sales of 1.5M semaglutide pens in global rollout — a potential long‑term headwind to pricing and market share in lower‑cost segments. Indian’s Hetero targets annual sales of 1.5 million semaglutide pens in global rollout

Institutional Trading of Novo Nordisk A/S

Hedge funds have recently added to or reduced their stakes in the stock. True Wealth Design LLC lifted its position in Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares during the period. Guerra Advisors Inc acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $25,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $25,000. WealthCollab LLC lifted its holdings in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the period. Finally, American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $28,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on NVO shares. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a research note on Tuesday, March 3rd. Wolfe Research started coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating on the stock. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating and twenty have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.